Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag S/Adr (OP:BAYRY)

13.76 +0.13 (+0.95%)
Streaming Delayed Price Updated: 10:45 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bayer Ag S/Adr

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Is BridgeBio Pharma Stock Trading Higher On Friday? ↗
BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants... 
Via Benzinga
News headline image
BAYRY Stock Earnings: Bayer Meets EPS, Beats Revenue for Q2 2024 ↗
BAYRY stock results show that Bayer met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer ↗
Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance that product is safe. 
Via Benzinga
Topics Lawsuit
News headline image
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs ↗
Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery. 
Via InvestorPlace
News headline image
3 Small-Cap Stocks With Explosive 2X Growth Potential ↗
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
Via InvestorPlace
News headline image
Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M ↗
Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation. 
Via Benzinga
News headline image
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership ↗
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... 
Via Talk Markets
News headline image
European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday? ↗
European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW, Enel, Iberdrola. 
Via Benzinga
News headline image
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February ↗
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
Via Benzinga
Topics Data Breach
News headline image
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval ↗
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo. 
Via Benzinga
News headline image
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game ↗
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
News headline image
BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q1 2024 ↗
BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch ↗
Unlock the potential of AI in pharmaceuticals. With AI's help, the pharma industry could see $60B-$110B in annual economic value. Dive into the future of drug discovery and clinical development with... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned ↗
Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict over chemical contamination. This highlights broader legal battles over PCBs... 
Via Benzinga
News headline image
Alphabet, Nasdaq, Spotify, Teck Resources And A Major Financial Stock On CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Nasdaq, Inc. (NASDAQ: NDAQ) is 
Via Benzinga
News headline image
Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists ↗
Unlock AI-powered radiology solutions with Bayer AG and Google Cloud collaboration. Accelerate medical imaging innovations with gen AI tools for faster diagnoses. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds ↗
Corporate bonds offer yield opportunities and diversification away from equity investments. Investment-grade bonds are safer but lower yield, while high-yield bonds offer higher returns but from... 
Via Benzinga
Topics Bonds
News headline image
Bayer-Backed Boundless Bio Falls After IPO ↗
Shares of Boundless Bio fell almost 10% after raising about $100 million in the company's initial public offering. Bayer is one of the biggest investors for the therapeutics company. 
Via Talk Markets
News headline image
Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant ↗
Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential... 
Via Benzinga
News headline image
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits ↗
Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications. 
Via Benzinga
Topics Bankruptcy Lawsuit
News headline image
BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q4 2023 ↗
BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges ↗
Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing performance and flexibility. The company's focus and fiscal outlook for 2024. 
Via Benzinga
News headline image
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits ↗
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
Via InvestorPlace
News headline image
What's Going On With BridgeBio Pharma Stock On Monday? ↗
BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. 
Via Benzinga
News headline image
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out? ↗
BridgeBio will receive a tiered royalty on sales that begins at the low-30% range. 
Via Investor's Business Daily
News headline image
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? ↗
On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks. 
Via InvestorPlace
News headline image
3 Overextended Stocks That Need to Slash Their Dividends ASAP ↗
The most common attribute of overextended stocks other than carrying too much debt is dividends that are too big. 
Via InvestorPlace
News headline image
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
News headline image
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million ↗
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China... 
Via Talk Markets
News headline image
Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial ↗
Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer. 
Via Benzinga
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.